Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
0
Neutral
14
Bullish
0
Bearish
0
Neutral
46
Bullish
0
Bearish
0
Neutral
32
Bullish
0
Discovery themes featuring this stock
Dr Lalchandani Labs Limited is a diagnostic and healthcare service provider in Delhi/NCR, offering a range of pathology and diagnostic tests.
The company was established in 2011 and transitioned from a partnership firm to a limited company in 2017.
Dr Lalchandani Labs operates five fully equipped labs and fifteen collection centers, providing comprehensive diagnostic services.
The company has a significant presence in Delhi/NCR with partnerships in major hospitals and offers home collection services enhancing accessibility.
Dr Lalchandani Labs is NABL accredited and prioritizes high-tech diagnostic solutions, partnering with leading global suppliers.
Healthcare
Diagnostic Services
14 Cr
Low Risk
16.2
42.1
—
0.9
21.22
7.24
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Dr Lalchandani Labs Ltd (DLCL) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Dr Lalchandani Labs Limited is a diagnostic and healthcare service provider in Delhi/NCR, offering a range of pathology and diagnostic tests. The company was established in 2011 and transitioned from a partnership firm to a limited company in 2017. Dr Lalchandani Labs operates five fully equipped labs and fifteen collection centers, providing comprehensive diagnostic services. The company has a significant presence in Delhi/NCR with partnerships in major hospitals and offers home collection services enhancing accessibility. Dr Lalchandani Labs is NABL accredited and prioritizes high-tech diagnostic solutions, partnering with leading global suppliers.
Over the past 52 weeks, Dr Lalchandani Labs Ltd has traded between a low of ₹0.00 and a high of ₹21.22. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Dr Lalchandani Labs Ltd has a market capitalization of approximately 13.50. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Dr Lalchandani Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 16.23 and operates in the Healthcare sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 13.50 Cr, Dr Lalchandani Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Dr Lalchandani Labs Ltd operates in the Healthcare sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Dr Lalchandani Labs Ltd is 16.23. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
64.90 | 113 Cr | 5.50 | 1.10 | 0.00 | 18.49 | 23.03 | 13.19 | |
59.05 | 74 Cr | 10.60 | 1.46 | 0.00 | 35.97 | 39.64 | 0.00 | |
57.00 | 59 Cr | 28.93 | 8.11 | 0.00 | 16.62 | 13.17 | 13.75 | |
15.60 | 22 Cr | 10.99 | 0.32 | 0.00 | 3.32 | 6.57 | 2.69 | |
15.58 | 14 Cr | 16.23 | 0.94 | 0.00 | 4.53 | 3.40 | 2.92 | |
44.00 | 10 Cr | 23.16 | 1.14 | 0.00 | 5.19 | 7.65 | 4.22 | |
7.76 | 8 Cr | -8.26 | 0.43 | 0.00 | -3.76 | -1.02 | -2.81 |
Substantial Acquisition
Anuraag Gambhir acquired 1,300,000 equity shares of Dr. Lalchandani Labs Ltd via rights issue allotment on 02-Mar-2026, increasing his holding to 1,300,002 shares (15.05%); disclosure filed under SEBI Reg.29(1); BSE-listed.
Rights Issue Allotment
Board approved allotment of 4,304,000 equity shares at ₹10 each under the rights issue (opened Feb 4, closed Feb 27, 2026), raising paid-up capital to ₹8,63,70,680.
Rights Issue Allotment
Board approved allotment of 43,04,000 equity shares at ₹10 each under the Rights Issue (opened Feb 4–closed Feb 27), raising ₹430.40 lakh and increasing paid-up equity capital to ₹8,63,70,680.
